Introduction: New Mexico, a state with a high incidence of opioid overdose deaths, requires certified nurse-midwives (CNMs) who prescribe controlled substances to use the statewide Prescription Monitoring Program (PMP). This study examined how frequently CNMs who practice in New Mexico and prescribe controlled substances use the PMP and the purposes for which they use it.
INTRODUCTION
Death by opioid overdose is a leading cause of accidental death in the United States. 1, 2 In 2016, more than 100 deaths per day occurred from an opioid overdose, 3, 4 and 40% were from commonly prescribed opioids. 1 Prescription opioid overdoses are a growing problem among women. Between 1999 and 2010, deaths from prescription painkillers among women increased by more than 400%, compared with a 265% increase among men. 5 There has also been an increased incidence of opioid use disorder among pregnant women and a rise in the number of cases of neonatal abstinence syndrome. 5 Women are more likely than men to have chronic pain and to be prescribed opioids at higher doses and for a longer duration. 5 Women may become opioid dependent more quickly than men. 5 Accordingly, providers of women's health care services have an important role to play in reducing the risks of substance use disorders.
The death rate from drug overdose in New Mexico (per 100,000 population) tripled between 1990 and 2016 and exceeded the US death rate in every year during that interval. 6 Over the past decade, there has been a significant increase in deaths due to overdose of prescription drugs, whereas deaths from overdose of illicit drugs have remained relatively stable. 6 From 2010 to 2014, prescription drugs caused more than half (53%) of drug overdose deaths in the state compared with one-third (33%) caused by illicit drugs (14% involved both). 7 During that interval, the death rate for women aged 25 to 64 years was 31 per 100,000 (95% CI, 28.9-33.1). 7 Death rates from opioid overdose among women of all ages in New Mexico substantially exceed those for the United States as a whole ( Figure 1 ). 8 
Prescription Monitoring Programs
Prescription monitoring programs (PMPs) are statewide databases that collect, monitor, and analyze electronically transmitted information from pharmacies and health care providers on dispensed prescriptions of controlled substances. [9] [10] [11] [12] The purpose of a PMP is to provide authorized users with the ability to review a patient's controlled substance prescription history to detect and reduce diversion, abuse, and misuse of controlled substance prescriptions and prevent overdose deaths. 13, 14 PMPs are also used to monitor prescribers and prevent overprescribing and fraudulent prescribing.
14 Policies to control overprescribing, such as use of the PMP, are a form of secondary prevention aimed at treating a disease early on. Efforts to identify and treat individuals addicted to opioids early in the course of the disease are likely to reduce the risk of overdose, the transition to injection opioid use, and medical morbidities. 15 Additional ✦ This study examined prescribing practices and compliance with state requirements for controlled substance prescribing among certified nurse-midwives (CNMs) in New Mexico.
✦ More than 25% of respondents who prescribe controlled substances reported doing so at least weekly, and approximately half do at least monthly.
✦ Some CNMs in New Mexico may not be utilizing the state's Prescription Monitoring Program in optimal fashion.
resources pertaining to prescribing and monitoring of controlled substances are included in Appendix 1. In 2005, the New Mexico Board of Pharmacy implemented a PMP that required all nonfederal pharmacies in the state to report all filled prescriptions for controlled substances. Prior to 2017, practitioners authorized to prescribe controlled substances were required to check the PMP when prescribing a controlled substance for a patient with chronic pain. In 2016, the New Mexico legislature enacted a statute requiring all licensed health care practitioners who prescribe controlled substances 16 to check the PMP 1) before prescribing or dispensing "an opioid for the first time to a patient" 16(p2) (if the prescription is for a Ͼ4-day supply) and 2) for continual opioid prescribing or dispensing, at a minimum, every 3 months. Practitioners are not required to check the PMP "when prescribing an opioid to a patient in a nursing facility or in hospice care." 16(p3) The statute also directed that licensing boards for practitioners licensed or authorized to prescribe or dispense opioids implement the PMP requirements in their respective practice rules. 19 REDCap is a secure, web-based application designed to support data capture for research studies. Ethical approval as an exempt study was granted by the University of New Mexico's institutional review board.
The survey was created and administered by the investigators and consisted of 24 questions (see Supporting Information: Appendix S1). Questions were categorical, some of which allowed multiple options to be chosen. Participants who worked as a CNM in only one New Mexico county selected the county from a dropdown list; an open-ended question allowed participants working in more than one county to write them in. Branching logic was used where appropriate (eg, CNMs who did not have a US Drug Enforcement Administration [DEA] registration were not asked questions about prescribing practices). Because there were no validated surveys with this focus, survey questions were developed by the investigators to address concerns raised by the Certified Nurse-Midwives Advisory Board and the NMDOH. The survey was tested prior to launch of the study by the research team and members of the NMDOH. There was no formal assessment of reliability or content validity.
Email addresses of all CNMs licensed to practice in the state of New Mexico were provided by the NMDOH. An introductory email with a brief description of the study was sent to all CNMs on the list (N = 210). A follow-up email included the approved consent letter, an invitation to participate in the study, and a link to the study. Participation in the survey was voluntary. Consent was obtained by including a statement in the survey invitation indicating that by answering the survey online, the CNM was agreeing to participate in the research study. A reminder email was sent out at the halfway point of the survey time frame. The survey was open for a total of 6 weeks. Data were evaluated using SPSS version 24.0 (IBM Corporation, Armonk, NY) and reported as descriptive statistics.
RESULTS
A total of 83 CNMs answered the survey (39.5% response rate). More than 85% of respondents identified as white; Hispanic or Latina and American Indian respondents each constituted approximately 5% of the sample (Table 1) . Most respondents held a master's degree, and relatively few reported dual certification as a nurse practitioner. Almost two-thirds of respondents reported being in practice for more than 10 years.
Approximately three-fourths of respondents (64/83) provided direct, clinical care to patients in New Mexico, and 20% of these respondents worked in a rural area (Table 2) . Most respondents worked in practices that provided gynecologic care, prenatal care, in-hospital birth care, and reproductive health services, all of which the respondents provided and which fell within their scope of practice. Six respondents worked in services that provided substance use disorder services, but only 2 of them provided this care as part of their own scope of practice.
All but 2 respondents providing clinical care in New Mexico (62/64) had a DEA registration number (Table 2 ) and were registered in the PMP (97%, 62/64). Table 3 shows data pertaining to PMP registration and use by CNMs currently practicing in New Mexico who had DEA registration numbers and Abbreviations: CNM, certified nurse-midwife; CNP, certified nurse practitioner; DNP, Doctor of Nursing Practice; PhD, Doctor of Philosophy. a n = 82 because of missing data.
were registered in the PMP (n = 62) and the subset of that group who were currently prescribing controlled substances (n = 56). Approximately one-quarter reported logging into the PMP less frequently than every 6 months for any reason, and 7% reported never logging in. Approximately 40% had never run a self-report, and more than one-quarter had never checked the PMP for patient alerts. More than half of those who prescribed controlled substances reported prescribing from all schedules; for those who did not, Schedule II and III drugs were prescribed to a greater extent than Schedule IV or V drugs. 20 Slightly more than half prescribed a controlled substance infrequently (every 2 to 6 months) or very infrequently (less than every 6 months; Table 4 ). With respect to prescriptions for controlled substances for their own patients, fewer than 30% (16/56) reported checking the PMP every time they prescribed a controlled substance unless an exception applied (eg, a prescription of no more than 4 days' duration); the remaining 70% did so less often or not at all (Table 4) . Among the subset who reported prescribing controlled substances at least once a month (n = 26), fewer than half (11/26; 42%) reported logging into the PMP at least monthly, 38% (10/26) replied that they never ran a self-report, 27% (7/26) replied that they never checked the PMP website for patient alerts, and, with respect to their own prescribing, 35% (9/26) checked the PMP less frequently than every 6 months. 
DISCUSSION
To our knowledge, this study is the first to describe prescribing practices and compliance with state prescription monitoring requirements among CNMs. Results from this study show that CNMs in New Mexico are aware of the PMP and that nearly all who are required to have a PMP account do. However, some are not checking the PMP as often as required by statute. 16 For example, more than 40% of the participants who prescribed controlled substances did so at least monthly, but more than half of that subset ran PMP self-reports or checked for patient alerts less often than every 6 months, and approximately one-third of them checked the PMP less often than every 6 months when prescribing a controlled substance. It is possible that PMP use by some CNMs is in accordance with earlier practice regulations, which required checking the PMP only when prescribing controlled substances for patients with chronic pain. 17 The newer statutory requirements that went into effect in January 2017 16 have been incorporated into practice regulations for physicians (NMAC 16.10.14), 21 dentists (NMAC 16.5.57), 22 and advanced practice nurses other than CNMs (NMAC 16.12.9) , 23 whereas the corresponding changes for CNMs are still in rulemaking. 18 However, we found that nearly all respondents who should have been registered with the PMP were, and the statutory change was well publicized. Data on the impact of state policy and system-level interventions related to prescribing practices and PMP use are limited and inconsistent, 24 with some studies showing improvements in prescribing practices and others showing no difference. 25, 26 For example, one study found that implementation of a PMP was associated with a more than 30% reduction in the rate of prescribing of Schedule II opioids, but prescribing of Schedule III opioids was unchanged. 9 The effect of PMPs varied significantly when state-by-state data were examined. 25 Across states, PMPs have different designs, requirements, and operations, making it difficult to evaluate their overall effectiveness. 27 There is also considerable variability in PMP legislative components as well as in states' implementation strategies. 28 Almost every state has a PMP, and as of January 2018, 37 states reported having legislation requiring opioid prescribers or dispensers to report to PMPs. 10, 29 An examination of 3 states that mandated PMP use showed a rapid increase in provider enrollment and utilization of the PMP, better identification of potential physician-shoppers and those in need of intervention for opioid use disorders, and improved medically indicated opioid prescribing.
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Limitations
This study has several limitations. Because the study was conducted in a single state, the extent to which results may be generalizable to CNM prescribing practices or PMP use elsewhere is unknown. All CNMs licensed to practice in the state were invited to participate, but the response rate was approximately 40%. Several studies have shown that response rates to electronic surveys of health care providers are significantly lower (7%-15% less) than response rates for mail or mixed-media studies. 31 Some CNMs may not have responded because they were not currently practicing in the state, not currently engaged in clinical practice, or not prescribing controlled substances. However, it is likely that other CNMs actively practicing and prescribing controlled substances did not participate for unknown reasons. Therefore, participants constituted a self-selected convenience sample with attendant risks of response biases.
We developed the survey questions ourselves because we could not find a validated survey with this focus. Because the survey used a combination of single items and branching logic items, assumptions for conventional assessment of internal consistency reliability were not met, and we did not formally assess content validity. We thought that by using the term prescribing, the intent and focus of the survey on prescribing in an outpatient setting or at hospital discharge would be clear. However, we received 2 inquiries requesting clarification of whether prescribing controlled substances also included controlled substances used in an inpatient setting (eg, parenteral opioids for pain management during labor). Therefore, it is possible that some participants took prescribing to include ordering pain medication in labor. If so, this may have resulted in some estimates indicating that CNMs were prescribing controlled substances more often than they actually do.
In hindsight, several questions were vague or ambiguous in intent. For example, a question intended to assess knowledge about the PMP merely asked if respondents understood what it was, and all respondents who were asked that question (ie, those in clinical practice who had DEA registration numbers) indicated that they did, which was uninformative because of zero variance. With respect to prescriptions for controlled substances for their own patients, it is possible that some respondents routinely limited prescription duration to 4 days or less to avoid having to check the PMP before prescribing. Therefore, the observed percentages for lessfrequent checking in Table 4 are not necessarily indicative of noncompliance with statutory requirements, despite apparent discordance with reported frequency of prescribing controlled substances. Whether some CNMs might be underprescribing for pain management to stay below the threshold for checking the PMP cannot be determined from the survey.
Implications and Recommendations
The NMDOH is aware of the results of this survey. Results of the study suggest a need for greater attention to the PMP requirements. Educational programs and facility-or practicebased quality improvement projects could be developed to address the importance of adherence to PMP requirements and to improve consistency of reporting. They could also emphasize the importance of the PMP for reducing risks of diversion or unauthorized use of controlled substances.
Because of the lack of research on CNM prescribing practices for controlled substances and the epidemic levels of opioid misuse and overdose nationwide, we recommend that a national survey on CNM controlled substance prescribing practices be conducted. Although differences in state regulations would need to be accounted for, a national survey could help to inform licensing boards about the prescribing practices of CNMs and assist legislators and regulators in implementing best practices nationwide. 32 Statewide monitoring of opioid prescribing is an important component of reducing illicit opioid use. 33 Improving prescribing practices of health care providers by consistent use of PMPs is only one tool for reducing risks of prescription overdose and death from opioids and other controlled substances. Other secondary prevention strategies include pain clinic laws to decrease inappropriate prescribing and improved screening techniques for substance abuse as well as mental health problems. 5, 34 Primary prevention strategies are also necessary. For example, among surgeons, wide variation has been reported in the amount and dosage of postoperative opioid prescriptions for the same procedure, and patients took far fewer doses than had been prescribed. 35 Development of evidence-based clinical guidelines for prescription amounts and durations and educating patients on safe disposal of unused pills are among recommendations for decreasing opportunities for misuse. 35 Lastly, ensuring the provision of harm reduction strategies, such as wider availability of opioid antagonists and greater access to effective and affordable treatment services, are key aspects of tertiary prevention for those with existing substance use disorders.
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CONCLUSION
It is important that CNMs educate themselves about statutory requirements for PMP participation as a component of best practices for treating pain and prescribing opioids. CNMs need to be in the forefront of best prescribing practices to help save the lives of women, prevent complications with their newborns, and prevent substance use disorders and overdose. Based on these research findings, we recommend that the NMDOH implement an educational program to ensure that CNMs licensed in the state are aware of the statutes and regulations that affect their prescribing of controlled substances and the associated PMP reporting requirements. More research is needed by regulatory boards in other states to determine whether CNMs across the United States are prescribing controlled substances in a safe and effective manner.
